ASPEN AEROGELS INC (ASPN) Fundamental Analysis & Valuation

NYSE:ASPN • US04523Y1055

Current stock price

3.06 USD
-0.17 (-5.26%)
At close:
3.03 USD
-0.03 (-0.98%)
Pre-Market:

This ASPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ASPN Profitability Analysis

1.1 Basic Checks

  • ASPN had negative earnings in the past year.
  • ASPN had a positive operating cash flow in the past year.
  • In the past 5 years ASPN reported 4 times negative net income.
  • ASPN had negative operating cash flow in 4 of the past 5 years.
ASPN Yearly Net Income VS EBIT VS OCF VS FCFASPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of ASPN (-62.12%) is worse than 97.59% of its industry peers.
  • The Return On Equity of ASPN (-99.85%) is worse than 87.95% of its industry peers.
  • ASPN has a worse Return On Invested Capital (2.43%) than 61.45% of its industry peers.
Industry RankSector Rank
ROA -62.12%
ROE -99.85%
ROIC 2.43%
ROA(3y)-33.6%
ROA(5y)-26.79%
ROE(3y)-57.54%
ROE(5y)-44%
ROIC(3y)N/A
ROIC(5y)N/A
ASPN Yearly ROA, ROE, ROICASPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • ASPN has a Operating Margin of 3.27%. This is in the lower half of the industry: ASPN underperforms 60.24% of its industry peers.
  • ASPN has a Gross Margin of 32.89%. This is in the better half of the industry: ASPN outperforms 66.27% of its industry peers.
  • In the last couple of years the Gross Margin of ASPN has grown nicely.
Industry RankSector Rank
OM 3.27%
PM (TTM) N/A
GM 32.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y82.93%
GM growth 5Y3.11%
ASPN Yearly Profit, Operating, Gross MarginsASPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ASPN Health Analysis

2.1 Basic Checks

  • ASPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ASPN has more shares outstanding
  • The number of shares outstanding for ASPN has been increased compared to 5 years ago.
  • Compared to 1 year ago, ASPN has a worse debt to assets ratio.
ASPN Yearly Shares OutstandingASPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
ASPN Yearly Total Debt VS Total AssetsASPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -0.66, we must say that ASPN is in the distress zone and has some risk of bankruptcy.
  • ASPN's Altman-Z score of -0.66 is on the low side compared to the rest of the industry. ASPN is outperformed by 87.95% of its industry peers.
  • ASPN has a debt to FCF ratio of 46.99. This is a negative value and a sign of low solvency as ASPN would need 46.99 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 46.99, ASPN perfoms like the industry average, outperforming 40.96% of the companies in the same industry.
  • ASPN has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ASPN (0.31) is better than 77.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 46.99
Altman-Z -0.66
ROIC/WACC0.21
WACC11.79%
ASPN Yearly LT Debt VS Equity VS FCFASPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.94 indicates that ASPN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 3.94, ASPN belongs to the best of the industry, outperforming 91.57% of the companies in the same industry.
  • ASPN has a Quick Ratio of 3.33. This indicates that ASPN is financially healthy and has no problem in meeting its short term obligations.
  • ASPN has a Quick ratio of 3.33. This is amongst the best in the industry. ASPN outperforms 93.98% of its industry peers.
Industry RankSector Rank
Current Ratio 3.94
Quick Ratio 3.33
ASPN Yearly Current Assets VS Current LiabilitesASPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ASPN Growth Analysis

3.1 Past

  • ASPN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -223.08%.
  • The Revenue for ASPN has decreased by -40.11% in the past year. This is quite bad
  • The Revenue has been growing by 22.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-223.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.57%
Revenue 1Y (TTM)-40.11%
Revenue growth 3Y14.54%
Revenue growth 5Y22%
Sales Q2Q%-66.42%

3.2 Future

  • ASPN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.94% yearly.
  • Based on estimates for the next years, ASPN will show a quite strong growth in Revenue. The Revenue will grow by 19.26% on average per year.
EPS Next Y3.34%
EPS Next 2Y33.78%
EPS Next 3Y52.26%
EPS Next 5Y49.94%
Revenue Next Year-27.97%
Revenue Next 2Y0%
Revenue Next 3Y18.24%
Revenue Next 5Y19.26%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ASPN Yearly Revenue VS EstimatesASPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
ASPN Yearly EPS VS EstimatesASPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. ASPN Valuation Analysis

4.1 Price/Earnings Ratio

  • ASPN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASPN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASPN Price Earnings VS Forward Price EarningsASPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • ASPN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ASPN is cheaper than 86.75% of the companies in the same industry.
  • ASPN's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 94.4
EV/EBITDA 6.74
ASPN Per share dataASPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ASPN's earnings are expected to grow with 52.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.78%
EPS Next 3Y52.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASPN Dividend Analysis

5.1 Amount

  • ASPN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASPN Fundamentals: All Metrics, Ratios and Statistics

ASPEN AEROGELS INC

NYSE:ASPN (3/20/2026, 8:04:00 PM)

Premarket: 3.03 -0.03 (-0.98%)

3.06

-0.17 (-5.26%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners71.67%
Inst Owner Change-0.67%
Ins Owners1.11%
Ins Owner Change1.04%
Market Cap253.46M
Revenue(TTM)271.10M
Net Income(TTM)-305.28M
Analysts76.92
Price Target6.63 (116.67%)
Short Float %10.8%
Short Ratio4.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-101.12%
Min EPS beat(2)-176.85%
Max EPS beat(2)-25.4%
EPS beat(4)2
Avg EPS beat(4)-32.06%
Min EPS beat(4)-176.85%
Max EPS beat(4)57.28%
EPS beat(8)6
Avg EPS beat(8)89.76%
EPS beat(12)10
Avg EPS beat(12)72.04%
EPS beat(16)10
Avg EPS beat(16)45.6%
Revenue beat(2)1
Avg Revenue beat(2)2.56%
Min Revenue beat(2)-0.36%
Max Revenue beat(2)5.47%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-6.73%
Max Revenue beat(4)5.47%
Revenue beat(8)5
Avg Revenue beat(8)5.37%
Revenue beat(12)7
Avg Revenue beat(12)4.61%
Revenue beat(16)9
Avg Revenue beat(16)3.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)-58.98%
EPS NY rev (3m)-61.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.37%
Revenue NY rev (1m)-17.19%
Revenue NY rev (3m)-19.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF 94.4
P/OCF 4.84
P/B 0.83
P/tB 0.83
EV/EBITDA 6.74
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)0.03
FCFY1.06%
OCF(TTM)0.63
OCFY20.68%
SpS4.26
BVpS3.69
TBVpS3.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.12%
ROE -99.85%
ROCE 2.74%
ROIC 2.43%
ROICexc 3.79%
ROICexgc 3.79%
OM 3.27%
PM (TTM) N/A
GM 32.89%
FCFM 0.76%
ROA(3y)-33.6%
ROA(5y)-26.79%
ROE(3y)-57.54%
ROE(5y)-44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y82.93%
GM growth 5Y3.11%
F-Score4
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 46.99
Debt/EBITDA 2.77
Cap/Depr 221.9%
Cap/Sales 14.1%
Interest Coverage 0.81
Cash Conversion 154.39%
Profit Quality N/A
Current Ratio 3.94
Quick Ratio 3.33
Altman-Z -0.66
F-Score4
WACC11.79%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-223.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.57%
EPS Next Y3.34%
EPS Next 2Y33.78%
EPS Next 3Y52.26%
EPS Next 5Y49.94%
Revenue 1Y (TTM)-40.11%
Revenue growth 3Y14.54%
Revenue growth 5Y22%
Sales Q2Q%-66.42%
Revenue Next Year-27.97%
Revenue Next 2Y0%
Revenue Next 3Y18.24%
Revenue Next 5Y19.26%
EBIT growth 1Y-73.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.83%
EBIT Next 3Y33.78%
EBIT Next 5Y20.89%
FCF growth 1Y102.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y640.1%
OCF growth 3YN/A
OCF growth 5YN/A

ASPEN AEROGELS INC / ASPN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASPEN AEROGELS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASPN.


Can you provide the valuation status for ASPEN AEROGELS INC?

ChartMill assigns a valuation rating of 2 / 10 to ASPEN AEROGELS INC (ASPN). This can be considered as Overvalued.


How profitable is ASPEN AEROGELS INC (ASPN) stock?

ASPEN AEROGELS INC (ASPN) has a profitability rating of 1 / 10.


How financially healthy is ASPEN AEROGELS INC?

The financial health rating of ASPEN AEROGELS INC (ASPN) is 5 / 10.


What is the expected EPS growth for ASPEN AEROGELS INC (ASPN) stock?

The Earnings per Share (EPS) of ASPEN AEROGELS INC (ASPN) is expected to grow by 3.34% in the next year.